Prosecution Insights
Last updated: November 04, 2026
Application No. 18/887,203

RETROVIRAL TRANSDUCTION USING POLOXAMERS

Non-Final OA §DP
Filed
Sep 17, 2024
Priority
Feb 29, 2012 — EU 12157461.0 +5 more
Examiner
KINSEY WHITE, NICOLE ERIN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sirion Biotech GmbH
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
511 granted / 879 resolved
-1.9% vs TC avg
Strong +16% interview lift
Without
With
+16.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
45 currently pending
Career history
917
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
32.9%
-7.1% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
30.9%
-9.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 879 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Specification Applicant should update the first paragraph of the specification to provide the correct status of application number 18/085751 (i.e., patented). Claim Objections Claim 1 is objected to because of the following informalities: Claim 1 should recite “selected from the group consisting of polycationic polymers and polycationic peptides”. Appropriate correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 and 6-15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3-4, 6 and 8-9 of U.S. Patent No. 12385066. The instant claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein "about" refers to -10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, and wherein said poloxamer is in a fluid state during the contacting step and wherein said target cell is not brought into contact with one or more polycationic substances selected from the group of polycationic polymers and polycationic peptides. The patented claims are directed to a method of gene therapy comprising: (i) transducing a target cell, said transducing comprising contacting the target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein “about” refers to—10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C.sub.2H.sub.4O).sub.x(C.sub.3H.sub.6O).sub.z(C.sub.2H.sub.4O).sub.yH, wherein the average value of z is at least 43, and the average value of x+y is at least 230, and wherein said poloxamer is in a fluid state during the contacting step, wherein after said contacting step said retroviral vector enters said cell, and (ii) using the transduced cell for a gene therapy application. Patented claim 1 does not recite that the target cell is brought into contact with one or more polycationic substances. Instant claims 1, 6-9 and 13 are taught by patented claims 1 and 8. Instant claims 10-11 are taught by patented claim 3. Instant claim 12 is taught by patented claim 4. Instant claim 14 is taught by patented claim 6. Instant claim 15 is taught by patented claim 9. Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 1-13 and 15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 9-10 and 15-16 of U.S. Patent No. 11591617. The instant claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein "about" refers to -10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, and wherein said poloxamer is in a fluid state during the contacting step and wherein said target cell is not brought into contact with one or more polycationic substances selected from the group of polycationic polymers and polycationic peptides. The patented claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell ex vivo or in vitro with a retroviral vector and a poloxamer, the poloxamer having a molecular weight of 12.8 kDa to about 15 kDa, wherein the poloxamer has the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, wherein the value of x+y is between 220 to 360, and the value of z is between 42 to 52, wherein the poloxamer is in a fluid state during the contacting step, wherein the poloxamer is provided at a concentration of about 50 to 5000 μg/ml, and the target cells contacted with the retroviral vector and the poloxamer exhibit a higher transduction rate without noticeable toxicity compared with target cells contacted with the retroviral vector without the poloxamer under the same conditions. Patented claims 1 and 15 do not recite that the target cell is brought into contact with one or more polycationic substances. Instant claims 1, 6-9, 13 and 15 are taught by patented claims 1 and 15. Instant claims 2-5 are taught by patented claims 2-5, respectively. Instant claim 10 is taught by patented claims 1, 15 and 16. Instant claim 11 is taught by patented claim 9. Instant claim 12 is taught by patented claim 10. Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 1-13 and 15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 11 and 12 of U.S. Patent No. 10815498. The instant claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein "about" refers to -10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, and wherein said poloxamer is in a fluid state during the contacting step and wherein said target cell is not brought into contact with one or more polycationic substances selected from the group of polycationic polymers and polycationic peptides. The patented claims are directed to a method for enhancing transduction efficiency of a retroviral vector into a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa, wherein the poloxamer is provided at a concentration of about 50 to 5000 μg/ml and is in a fluid state during the contacting step, and further wherein the target cells contacted with the retroviral vector and the poloxamer exhibit a higher transduction rate without noticeable toxicity, compared with target cells contacted with the retroviral vector without the poloxamer under the same conditions [patented claim 1], wherein the poloxamer has the formula HO—[CH2CH2O]x-[CH2C2H4O]z-[CH2CH2O]y, wherein x+y=265.45 and z=50.34 on average; or wherein the poloxamer has the formula HO—[CH2CH2O]x-[CH2C2H4O]z-[CH2CH2O]y, wherein x+y=236.36 and z=44.83 on average [patented claim 6]. Patented claim 1 does not recite that the target cell is brought into contact with one or more polycationic substances. Instant claims 1, 6-10, 13 and 15 are taught by patented claims 1 and 6. Instant claims 2-5 are taught by patented claims 2-5, respectively. Instant claims 11-12 is taught by patented claims 11-12, respectively. Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 1-13 and 15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 10-13 of U.S. Patent No. 9771599. The instant claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein "about" refers to -10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, and wherein said poloxamer is in a fluid state during the contacting step and wherein said target cell is not brought into contact with one or more polycationic substances selected from the group of polycationic polymers and polycationic peptides. The patented claims are directed to a method for transducing a target cell, the method comprising the step of contacting a target cell ex vivo or in vitro with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa, wherein the poloxamer is in a fluid state during transduction of the target cell [patented claim 1], wherein the poloxamer has the formula HO-[CH2CH2O]x-[CH2C2H4O]z-[CH2CH2O]y, wherein x+y=265.45 and z=50.34 on average; or wherein the poloxamer has the formula HO-[CH2CH2O]x-[CH2C2H4O]z-[CH2CH20]y, wherein x+y=236.36 and z=44.83 on average [patented claim 6], wherein the poloxamer is in a fluid state during the contacting step [patented claim 13]. Patented claim 1 does not recite that the target cell is brought into contact with one or more polycationic substances. Instant claims 1, 6-9, 13 and 15 are taught by patented claims 1, 6 and 13. Instant claims 2-5 are taught by patented claims 2-5, respectively. Instant claims 10-12 are taught by patented claims 10-12, respectively. Although the claims at issue are not identical, they are not patentably distinct from each other. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicole Kinsey White whose telephone number is (571)272-9943. The examiner can normally be reached M to Th 6:30 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NICOLE KINSEY WHITE/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Sep 17, 2024
Application Filed
Oct 01, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735752
Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof
4y 9m to grant Granted Sep 15, 2026
Patent 12735755
COMPOSITION, KIT, AND METHOD FOR DETECTING AND TYPING CORONAVIRUSES
4y 0m to grant Granted Sep 15, 2026
Patent 12734235
AAV5-BASED VACCINE AGAINST SARS-COV-2
3y 6m to grant Granted Sep 15, 2026
Patent 12723261
A PROCESS FOR PRODUCING A PLURALITY OF NEDDYLATION SITE MODIFIED AAV VECTORS
5y 3m to grant Granted Sep 01, 2026
Patent 12724028
SELF-ASSEMBLING PROTEIN NANOCAGE DECORATED WITH ANTIBODIES (SAPNA) AND PARTS THEREOF
4y 10m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
75%
With Interview (+16.5%)
3y 3m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month